 Immunome Inc NASDAQ: IMNM has announced that its three-antibody cocktail IMM-BCP-01 has demonstrated potent neutralizing activity against COVI-19 Delta variant in pre-clinical pseudovirus testing. Furthermore, IMM-BCP-01 showed in-vitro activity via non-neutralizing mechanisms, such as complement fixation, which Immunome expects will enable viral clearance. 